One thing is the theory. Another is real life.

Studying bioethics does not necessarily make one ethical. This seems to be the lesson from a huge Wall Street insider trading scandal. Prosecutors allege that Mathew Martoma, 38, a former porfolio manager for CR Intrinsic Investors, an affiliate of SAC Capital Advisors, one of the world’s biggest hedge funds, persuaded a researcher to give him information about an Alzheimer’s disease drug trial. Having learned before anyone else that the drug had failed, he made profits and avoided losses totalling about US$276 million.

The news service AP described the incident as “one of the biggest ethical lapses in Wall Street's history”.

Martoma did his undergraduate degree at Duke University and then worked for the National Institutes of Health. He later attended Harvard Law School, although he left without completing his degree to attend Stanford Business School. While at Harvard, he wrote two papers on medical ethics.

His supervisor at the NIH, the well-known Dartmouth bioethicist Ronald Green told AP, "I think one of the reasons he was brought in for this function [in the NIH] just after college is he had very good training in bioethics and he's a congenial person."

In 2006, when Martoma was working for CR, he met University of Michigan medical professor Sidney Gilman and persuaded him to leak confidential information about the a joint trial by drug companies Elan Corp. and Wyeth.

Martoma’s lawyer insists that his client’s information was based on dogged research. "I would say, having studied ethics in the biomed area, that he is keenly aware of what's right and what's wrong, and we do not believe he stepped across the line."

This article is published by Michael Cook and under a Creative Commons licence. You may republish it or translate it free of charge with attribution for non-commercial purposes following these guidelines. If you teach at a university we ask that your department make a donation. Commercial media must contact us for permission and fees. Some articles on this site are published under different terms.

comments powered by Disqus

 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed

 Best of the web

 Recent Posts
Is ‘financial abortion’ an idea whose time has come?
10 Dec 2016
The battle continues over the A-List embryos
10 Dec 2016
Nitschke ramps up campaign for unrestricted suicide
10 Dec 2016
Victoria to debate assisted suicide
10 Dec 2016
UK scientists to push for 28-day limit on cultivation of embryos
10 Dec 2016